Analyst Ratings for GlaxoSmithKline (GSK)
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
N/A
Avg. $ Target:
N/A
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/7/2013 | Liberum | Upgrade | Hold (Sell) |
N/A (N/A) |
51.18 | 51.48 | 0.59% | Details |
| 5/28/2013 | Deutsche Bank | Upgrade | Buy (Hold) |
N/A (N/A) |
52.97 | 51.48 | -2.81% | Details |
| 2/28/2013 | Morgan Stanley | Downgrade | Underweight (Equalweight) |
N/A (N/A) |
44.27 | 51.48 | 16.29% | Details |
| 1/29/2013 | Barclays | Upgrade | Overweight (Equalweight) |
N/A (N/A) |
44.56 | 51.48 | 15.53% | Details |
| 9/19/2012 | Exane BNP Paribas | Downgrade | Underperform (Outperform) |
N/A (N/A) |
47.11 | 51.48 | 9.28% | Details |
| 8/28/2012 | UBS | Downgrade | Neutral (Buy) |
N/A (N/A) |
46.49 | 51.48 | 10.73% | Details |
| 8/22/2012 | JPMorgan | Downgrade | Underweight (Neutral) |
N/A (N/A) |
46.07 | 51.48 | 11.74% | Details |
| 8/13/2012 | Jefferies | Downgrade | Hold (Buy) |
N/A (N/A) |
46.84 | 51.48 | 9.91% | Details |
| 8/10/2012 | Cowen | Downgrade | Neutral (Outperform) |
N/A (N/A) |
46.69 | 51.48 | 10.26% | Details |
| 5/10/2012 | Societe Generale | New Coverage | Buy (N/A) |
N/A (N/A) |
45.50 | 51.48 | 13.14% | Details |
| 5/31/2011 | Goldman Sachs | Downgrade | Sell (N/A) |
N/A (N/A) |
43.49 | 51.48 | 18.37% | Details |
| 1/11/2011 | Citi | Downgrade | Neutral (N/A) |
N/A (N/A) |
38.77 | 51.48 | 32.78% | Details |
| 12/7/2010 | Credit Suisse | Upgrade | Neutral (N/A) |
N/A (N/A) |
39.08 | 51.48 | 31.73% | Details |
| 9/7/2010 | BofA/Merrill Lynch | Upgrade | Buy (N/A) |
N/A (N/A) |
39.29 | 51.48 | 31.03% | Details |
